ethyl 2-(1,1'-biphenyl-4'-ol-4-oxy) acetate | 851335-52-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-(1,1'-biphenyl-4'-ol-4-oxy) acetate
• 英文别名: ethyl (4'-hydroxybiphenyl-4-yloxy)acetate；ethyl 2-[4-(4-hydroxyphenyl)phenoxy]acetate
• CAS: 851335-52-9
• 化学式: C₁₆H₁₆O₄
• 分子量: 272.301
• InChiKey: JVCXHXCAEFNPTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-(1,1'-biphenyl-4'-ol-4-oxy) acetate 在 potassium carbonate 、 sodium hydroxide 作用下， 以 丙酮 为溶剂， 生成 2-[4-[4-[2-(Dimethylamino)ethoxy]phenyl]phenoxy]acetic acid;hydrochloride
  参考文献：
  名称：

  3,3′-Disubstituted bipolar biphenyls as inhibitors of nuclear receptor coactivator binding

  摘要：

  A series of bipolar biphenyl compounds was synthesized as proteomimetic analogs of the LXXLL pentapeptide motif responsible for the binding of coactivator proteins to the nuclear hormone receptor coactivator binding domain. These compounds were subjected to multiple in vitro assays to evaluate their effectiveness as competitive binding inhibitors. The results from this initial study indicate that these proteomimetics possess the ability to inhibit this protein-protein interaction. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.007
• 作为产物：
  描述：

  4-溴苯酚 在 二氯双(三邻甲苯膦)合钯(II) 、 sodium hydride 、 sodium carbonate 、 三(邻甲基苯基)磷 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 2.0h， 生成 ethyl 2-(1,1'-biphenyl-4'-ol-4-oxy) acetate
  参考文献：
  名称：

  4,4′-Unsymmetrically substituted 3,3′-biphenyl alpha helical proteomimetics as potential coactivator binding inhibitors

  摘要：

  A series of unsymmetrically substituted biphenyl compounds was designed as alpha helical proteomimetics with the aim of inhibiting the binding of coactivator proteins to the nuclear hormone receptor coactivator binding domain. These compounds were synthesized in good overall yields in seven steps starting from 2-bromoanisole. The final products were evaluated using cotransfection reporter gene assays and mammalian two-hybrid competitive inhibition assays to demonstrate their effectiveness as competitive binding inhibitors. The results from this study indicate that these proteomimetics possess the ability to inhibit coactivator-receptor interactions, but via a mixed mode of inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.10.051

文献信息

• AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1679304A1

  公开（公告）日：2006-07-12

  The present invention provides compounds represented by general formula (I): a prodrug thereof, or pharmaceutical acceptable salts thereof, wherein R1 is hydrogen or lower alkyl; each of R2 and R3 is independently hydrogen or lower alkyl; each of R4, R5 and R6 is independently hydrogen, halogen, lower alkyl or lower alkoxy; R7 is hydrogen or lower alkyl; R8 is hydrogen, halogen, lower alkyl, lower alkoxy, etc; R9 is -COR10, -A1-COR10, -O-A2-COR10, etc; Ar is optionally substituted phenyl or heteroaryl; and A is a bond, -OCH2-, etc, which exhibit potent and selective β3-adrenoceptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

  本发明提供了由通式（I）表示的化合物： 其前药，或其药用可接受的盐，其中R1是氢或较低的烷基；R2和R3中的每一个独立地是氢或较低的烷基；R4、R5和R6中的每一个独立地是氢、卤素、较低的烷基或较低的烷氧基；R7是氢或较低的烷基；R8是氢、卤素、较低的烷基、较低的烷氧基等；R9是-COR10、-A1-COR10、-O-A2-COR10等；Ar是可选择地取代的苯基或杂环芳基；A是键，-OCH2-等，具有强效和选择性的β3-肾上腺素受体刺激活性。本发明还提供了含有所述化合物的药物组合物，以及其用途。
• [EN] MODULATORS OF NUCLEAR RECEPTOR CO-REGULATORY PROTEIN BINDING<br/>[FR] MODULATEURS DE LIAISON PROTÉINIQUE DE CORÉGULATION DE RÉCEPTEUR NUCLÉAIRE
  申请人：UNIV NORTHEASTERN

  公开号：WO2009117739A1

  公开（公告）日：2009-09-24

  Disclosed are novel compounds and compositions for inhibition of androgen and estrogen receptor signaling, methods for inhibiting androgen signaling, methods for inhibiting estrogen signaling, methods for inhibiting the interaction between a co-regulatory protein and an androgen or estrogen receptor, and methods for treating cancer.

  揭示了用于抑制雄激素和雌激素受体信号传导的新化合物和组合物，用于抑制雄激素信号传导的方法，用于抑制雌激素信号传导的方法，用于抑制共调节蛋白与雄激素或雌激素受体相互作用的方法，以及用于治疗癌症的方法。
• [EN] NOVEL ANTITUMOUR COMPOUNDS WITH ANTIMITOTIC ACTIVITY<br/>[FR] NOUVEAUX COMPOSES ANTITUMORAUX A ACTIVITE ANTIMITOTIQUE
  申请人：PHARMACIA AB

  公开号：WO1995029155A1

  公开（公告）日：1995-11-02

  (EN) Novel N-acyl-aminoalkyl phenyl ether compounds having general formula (I), wherein A is an aromatic ring such as phenyl, thienyl, furyl, pyridyl; R1, R2 and R3 are selected from H, alkyl, halogen, electron acceptors and electron donors; m is 0, 1 or 2; R4 is H or lower alkyl; R5 is NR6R7, OR8 or lower alkyl or lower cycloalkyl; R6 and R7 are H or lower alkyl or lower cycloalkyl; R8 is lower alkyl or lower cycloalkyl; Y is O or S; n is 2 or 3; R9 is H or lower alkyl; X is O or CH2; R10, R11 and R12 are selected from H, 'alkyl', halogen, electron acceptors and electron donors or one of them may be (a), wherein Z is a bond, O, CO or CH2; and wherein B is an aromatic ring such as phenyl or pyridyl and R13, R14 and R15 are selected from H, 'alkyl', halogen, electron acceptors and electron donors, and pharmaceutically acceptable salts thereof. The invention also comprises pharmaceuticals, especially anticancer and/or antimitotic drugs, comprising one or more of the above-mentioned compounds.(FR) Nouveaux composés d'éther phénylique de N-acyl-aminoalkyle de la formule générale (I) dans laquelle A représente un cycle aromatique tel que phényle, thiényle, furyle, pyridyle; R1, R2 et R3 sont choisis entre H, alkyle, halogène, des accepteurs d'électrons et des donneurs d'électrons; m vaut 0, 1 ou 2; R4 représente H ou alkyle inférieur; R5 représente NR6R7, OR8 ou alkyle inférieur ou cycloalkyle inférieur; R6 et R7 représentent H ou alkyle inférieur ou cycloalkyle inférieur; R8 représente alkyle inférieur ou cycloalkyle inférieur; Y représente O ou S; n vaut 2 ou 3; R9 représente H ou alkyle inférieur; X représente O ou CH2; R10, R11 et R12 sont choisis entre H, 'alkyle', halogène, des accepteurs d'électrons et des donneurs d'électrons, ou l'un d'entre eux peut représenter (a), Z représentant une liaison, O, CO ou CH2; et B représente un cycle aromatique tel que phényle ou pyridyle, et R13, R14 et R15 sont choisis entre H, 'alkyle', halogène, des accepteurs d'électrons et des donneurs d'électrons; et leurs sels pharmaceutiquement acceptables. L'invention se rapporte également à des produits pharmaceutiques, en particulier des médicaments anticancéreux et/ou antimitotiques, comprenant au moins un des composés précités.

  （中文翻译）具有通式（I）的新型N-酰基-氨基烷基苯醚化合物，其中A是芳香环，如苯基，噻吩基，呋喃基，吡啶基；R1、R2和R3选自H，烷基，卤素，电子受体和电子给体；m为0、1或2；R4为H或较低的烷基；R5为NR6R7、OR8或较低的烷基或较低的环烷基；R6和R7为H或较低的烷基或较低的环烷基；R8为较低的烷基或较低的环烷基；Y为O或S；n为2或3；R9为H或较低的烷基；X为O或CH2；R10、R11和R12选自H、'烷基'、卤素、电子受体和电子给体，或其中一个可能是（a），其中Z为键，O，CO或CH2；B为芳香环，如苯基或吡啶基，R13、R14和R15选自H、'烷基'、卤素、电子受体和电子给体，以及其药学上可接受的盐。本发明还包括药物，特别是包含上述化合物之一或多个的抗癌和/或抗有丝分裂药物。
• Amino alcohol derivatives, medicinal composition containing the same, and use of these
  申请人：Kobayashi Junichi

  公开号：US20070078184A1

  公开（公告）日：2007-04-05

  The present invention provides compounds represented by general formula (I): a prodrug thereof, or pharmaceutical acceptable salts thereof, wherein R 1 is hydrogen or lower alkyl; each of R2 and R3 is independently hydrogen or lower alkyl; each of R 4 , R 5 and R 6 is independently hydrogen, halogen, lower alkyl or lower alkoxy; R 7 is hydrogen or lower alkyl; R 8 is hydrogen, halogen, lower alkyl, lower alkoxy, etc; R 9 is —COR 10 , -A 1 -COR 10 , —O-A 2 -COR 10 , etc; Ar is optionally substituted phenyl or heteroaryl; and A is a bond, —OCH 2 —, etc, which exhibit potent and selective β3-adrenoceptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

  本发明提供了由通式（I）表示的化合物：其前体，或其药学上可接受的盐，其中R1是氢或较低的烷基；R2和R3各自独立地是氢或较低的烷基；R4，R5和R6各自独立地是氢，卤素，较低的烷基或较低的烷氧基；R7是氢或较低的烷基；R8是氢，卤素，较低的烷基，较低的烷氧基等；R9是-COR10，-A1-COR10，-O-A2-COR10等；Ar是可选取代的苯基或杂环芳基；A是键，-OCH2-等，这些化合物表现出潜在和选择性的β3-肾上腺素能受体刺激活性。本发明还提供了含有上述化合物的药物组合物及其用途。
• MODULATORS OF NUCLEAR RECEPTOR CO-REGULATORY PROTEIN BINDING
  申请人：Hanson Robert N.

  公开号：US20110105608A1

  公开（公告）日：2011-05-05

  Disclosed are novel compounds and compositions for inhibition of androgen and estrogen receptor signaling, methods for inhibiting androgen signaling, methods for inhibiting estrogen signaling, methods for inhibiting the interaction between a co-regulatory protein and an androgen or estrogen receptor, and methods for treating cancer.

  本发明涉及一种新型化合物和组合物，用于抑制雄激素和雌激素受体信号传导，抑制雄激素信号传导的方法，抑制雌激素信号传导的方法，抑制共同调节蛋白与雄激素或雌激素受体之间相互作用的方法，以及治疗癌症的方法。